These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

863 related items for PubMed ID: 12036919

  • 1. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD.
    Cancer Res; 2002 Jun 01; 62(11):3093-9. PubMed ID: 12036919
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL, Earel JK, Griffith TS.
    Cancer Gene Ther; 2006 Jun 01; 13(6):628-32. PubMed ID: 16456549
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
    Déjosez M, Ramp U, Mahotka C, Krieg A, Walczak H, Gabbert HE, Gerharz CD.
    Cell Death Differ; 2000 Nov 01; 7(11):1127-36. PubMed ID: 11139287
    [Abstract] [Full Text] [Related]

  • 6. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 7. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).
    Pawlowski JE, Nesterov A, Scheinman RI, Johnson TR, Kraft AS.
    Anticancer Res; 2000 Jan 15; 20(6B):4243-55. PubMed ID: 11205254
    [Abstract] [Full Text] [Related]

  • 8. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
    Lane D, Cartier A, L'Espérance S, Côté M, Rancourt C, Piché A.
    Gynecol Oncol; 2004 Jun 01; 93(3):594-604. PubMed ID: 15196850
    [Abstract] [Full Text] [Related]

  • 11. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T.
    Int J Mol Med; 2006 Jul 01; 18(1):41-7. PubMed ID: 16786154
    [Abstract] [Full Text] [Related]

  • 12. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J.
    J Orthop Res; 2003 Sep 01; 21(5):949-57. PubMed ID: 12919886
    [Abstract] [Full Text] [Related]

  • 13. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X, Kandasamy K, Srivastava RK.
    Cancer Res; 2003 Mar 01; 63(5):1059-66. PubMed ID: 12615723
    [Abstract] [Full Text] [Related]

  • 14. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 15. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK, VanOosten RL, Griffith TS.
    Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266
    [Abstract] [Full Text] [Related]

  • 16. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
    Mori T, Doi R, Toyoda E, Koizumi M, Ito D, Kami K, Kida A, Masui T, Kawaguchi Y, Fujimoto K.
    Surgery; 2005 Jul 01; 138(1):71-7. PubMed ID: 16003319
    [Abstract] [Full Text] [Related]

  • 17. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT.
    Cancer Res; 2001 Feb 15; 61(4):1645-51. PubMed ID: 11245478
    [Abstract] [Full Text] [Related]

  • 18. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 19. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 20. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
    Abdollahi T, Robertson NM, Abdollahi A, Litwack G.
    Cancer Res; 2003 Aug 01; 63(15):4521-6. PubMed ID: 12907626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.